HenryRKranzlerMD
Psychiatry • Philadelphia, PAAddiction, Psychopharmacology, Clinical Pharmacology
Professor, Psychiatry, Perelman School of Medicine
Dr. Kranzler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3535 Market St, Suite 500
Philadelphia, PA 19104Phone+1 215-746-1943Fax+1 860-679-6736
Summary
- Dr. Henry Kranzler is a psychiatrist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania, Philadelphia Veterans Affairs Medical Center, and Penn Presbyterian Medical Center. He received his medical degree from Rutgers Robert Wood Johnson Medical School and has been in practice 35 years. He specializes in addiction and psychopharmacology and is experienced in genetics of addiction, pharmacotherapy of alcohol dependence, pharmacogenetics of heavy drinking.
Education & Training
University of ConnecticutResidency, Psychiatry, 1982 - 1986
Rutgers Robert Wood Johnson Medical SchoolClass of 1982
Certifications & Licensure
PA State Medical License 2010 - 2024
CT State Medical License 1984 - 2011- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Topiramate's Effects on Heavy Drinking Start of enrollment: 2015 May 01
- Placebo-controlled Trial of Bupropion for Smoking Cessation in Pregnant Women Start of enrollment: 2014 Oct 30
- A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers Start of enrollment: 2014 Dec 18
Publications & Presentations
PubMed
- Author Correction: Multivariate analysis of 1.5 million people identifies genetic associations with traits related to self-regulation and addiction.Richard Karlsson Linnér, Travis T Mallard, Peter B Barr, Sandra Sanchez-Roige, James W Madole
Nature Neuroscience. 2024-12-06 - 1 citationsComparing the psychometric properties of reward and relief drinking measures.Victoria R Votaw, Matthew R Pearson, Henry R Kranzler, Corey R Roos, Elizabeth A Yeater
Experimental and Clinical Psychopharmacology. 2024-12-01 - Application of polygenic scores to a deeply phenotyped sample enriched for substance use disorders reveals extensive pleiotropy with psychiatric and somatic traits.Emily E Hartwell, Zeal Jinwala, Jackson Milone, Sarah Ramirez, Joel Gelernter
Neuropsychopharmacology. 2024-12-01
Journal Articles
- Discovery of the First Genome-Wide Significant Risk Loci for Attention deficit/hyperactivity DisorderHenry R Kranzler, Hakon Hakonarson, Michael Gandal, Elise B Robinson, Nature
- Genome‐Wide Association Meta‐Analysis of Age at First Cannabis UseHenry R Kranzler, Joel Gelernter, Tamara L Wall, Addiction
- AUDIT‐C and ICD Codes as Phenotypes for Harmful Alcohol Use: Association with ADH1B Polymorphisms in Two U.S. PopulationsDavid A Fiellin, William C Becker, Joel Gelernter, Henry R Kranzler, Ning Sun, John Concato, Addiction
- Join now to see all
Authored Content
- F131. Genome-Wide Association Study Identifies Glutamate Ionotropic Receptor GRIA4 as a Risk Gene for Comorbid Nicotine Dependence and Major DepressionApril 2018
- F131. Genome-Wide Association Study Identifies Glutamate Ionotropic Receptor GRIA4 as a Risk Gene for Comorbid Nicotine Dependence and Major DepressionApril 2018
- Genome-Wide Association Study Identifies a Regulatory Variant of RGMA Associated with Opioid Dependence in European AmericansJanuary 2018
- Genome-Wide Association Study Identifies a Regulatory Variant of RGMA Associated with Opioid Dependence in European AmericansJanuary 2018
- Join now to see all
Press Mentions
GLP-1s Hold Promise for Addiction but Questions RemainDecember 5th, 2024- Moderate Drinking Does Not Protect Against Heart Disease or Diabetes, New Study FindsNovember 25th, 2024
- Binge Drinking May Be Curbed with a PillFebruary 14th, 2023
- Join now to see all
Grant Support
- Component V: Topiramante Treatment Of Problem DrinkersNational Institute On Alcohol Abuse And Alcoholism2008–2012
- Deep Sequencing Studies For Cannabis And Stimulant DependenceNational Institute On Drug Abuse2010–2011
- Genetics Of Cocaine DependenceNational Institute On Drug Abuse2006–2010
- Novel Approaches To Alcoholism Pharmacotherapy And RiskNational Institute On Alcohol Abuse And Alcoholism2002–2010
- Clinical Trial: Sertraline PharmacotherapyNational Center For Research Resources2008
- Targeted Naltrexone For Problem DrinkersNational Center For Research Resources2004–2008
- Genetics Of Opioid DependenceNational Center For Research Resources2004–2008
- Genetics Of Cocaine DependenceNational Center For Research Resources2004–2008
- Genetics Of Alcohol DependenceNational Center For Research Resources2004–2008
- Effects Of Aripiprazole On Subjective And Physiological Responses To AlcoholNational Center For Research Resources2007
- Sertraline PharmacotherapyNational Center For Research Resources2004–2007
- Targeted Naltrexone For Early Problem DrinkersNational Institute On Alcohol Abuse And Alcoholism2003–2007
- Sertraline Pharmacotherapy For Alcoholism SubtypesNational Institute On Alcohol Abuse And Alcoholism2003–2007
- Planning For A CTSA Application At The University Of ConnecticutNational Center For Research Resources2006
- Memantine For Alcohol Dependence: An Open-Label Pilot StudyNational Center For Research Resources2005–2006
- Naltrexone InjectionsNational Center For Research Resources2004
- Molecular Genetics And Drug DependenceNational Center For Research Resources2004
- Genetic Vulnerability Of Cocaine Associated PsychosisNational Center For Research Resources2004
- FinasterideNational Center For Research Resources2004
- Scientific Review And Evaluation AwardNational Institute On Alcohol Abuse And Alcoholism2002–2003
- Genetic Studies Of Naltrexone Response In AlcoholicsNational Center For Research Resources1999–2002
- Oral Versus Depot Naltrexone For Relapse PreventionNational Institute On Alcohol Abuse And Alcoholism1998–2002
- Long Acting Depot Formulation Of Naltrexone For Alcohol DependenceNational Center For Research Resources1998–2002
- Effect Of Tryptophan Depletion On Mood And Craving In Patients With DepressionNational Center For Research Resources1998–2002
- Nefazodone, Naltrexone And Placebo With Relapse Prevention Of AlcoholismNational Center For Research Resources1997–2002
- Association Of DRD3 Alleles And Cocaine UseNational Center For Research Resources1997–2002
- Opioid Neurotransmission And Risk Of AlcoholismNational Center For Research Resources1996–2002
- New Approaches To The Pharmacotherapy Of AlcoholismNational Institute On Alcohol Abuse And Alcoholism1997–2001
- Targeted Naltrexone For Early Problem DrinkersNational Institute On Alcohol Abuse And Alcoholism1996–2000
- Long-Acting Depot Formulation Of Naltrexone For Alcohol DependenceNational Center For Research Resources1997
- Randomized Clinical Trial Of GepironeNational Institute On Alcohol Abuse And Alcoholism1996–1997
- Molecular Genetic Studies Of Drug Abuse--Use Of HRRNational Institute On Drug Abuse1995–1996
- Matching Alcoholic Subtypes To Specific MedicationsNational Institute On Alcohol Abuse And Alcoholism1992–1996
External Links
- Henry Kranzlerhttp://www.med.upenn.edu/csa/bios_faculty.html#kranzler
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
